Skip to content

Comparison of the Analgesic Efficacy of Ropivacaine Combined with Dexamethasone or Dexmedetomidine in Fascia Iliaca Compartment Block for Elderly Patients Undergoing Total Hip Arthroplasty: A Randomized Controlled Trial

The Effect of Ropivacaine Combined with Dexmedetomidine or Dexamethasone on Postoperative Analgesia and Complications in Elderly Patients Undergoing Total Hip Arthroplasty via the Iliac Fascial Block

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114594
Enrollment
Unknown
Registered
2025-12-15
Start date
2025-05-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip replacement

Interventions

Group A: Ropivacaine 0.375% 40 mL + Dexamethasone 5 mg:Ultrasound-guided Fascia Iliaca Compartment Block (FICB), with 40 mL of the study drug or saline injected in a single shot under real-time ultras
Group B: Ropivacaine 0.375% 40 mL + Dexmedetomidine 1 µg/kg:Ultrasound-guided Fascia Iliaca Compartment Block (FICB), with 40 mL of the study drug or saline injected in a single shot under real-time u
Group C: Ropivacaine 0.375% 40 mL + Saline:Ultrasound-guided Fascia Iliaca Compartment Block (FICB), with 40 mL of the study drug or saline injected in a single shot under real-time ultrasound guidanc

Sponsors

Shaoxing Shangyu District Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.The age is >=65 years, gender unrestricted. 2.The patient is scheduled to undergo total hip replacement under general anesthesia or epidural anesthesia. 3.American Society of Anesthesiologists (ASA) classification I–III. 4.Preoperative cognitive function is normal, and the patient is able to correctly understand and use the pain assessment tool (VAS). 5.The patient voluntarily participates in this study and has signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Allergic to ropivacaine, dexmedetomidine, dexamethasone, or other related medications. 2.Severe heart, liver, or kidney dysfunction, or severe respiratory diseases. 3.Preoperative central or peripheral nervous system diseases affecting pain assessment. 4.Recent use of opioids, sedatives, or corticosteroids that may affect the study results. 5.Preoperative infection, coagulation disorders, or skin lesions at the iliac fascia block site. 6.Patients who refuse to participate or are unable to cooperate with the study.

Design outcomes

Primary

MeasureTime frame
Primary outcome: Duration of analgesia (from surgery end to first PCA request);Postoperative adverse reactions;

Secondary

MeasureTime frame
Pain scores (NRS);Postoperative opioid consumption: Record the total amount of sufentanil used in PCA and the use of rescue analgesics within 48 hours after surgery.;Postoperative hospital stay;Patient satisfaction;

Countries

China

Contacts

Public ContactXu Yang

Shaoxing Shangyu District Traditional Chinese Medicine Hospital

yx131031@126.com+86 150 6815 0427

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026